Koray Yalcin

Dr. Koray Yalcin


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2020 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
VUVedat Uygun
Vedat Uygun
GKGülsün Karasu
Gülsün Karasu
HDHayriye Daloğlu
Hayriye Daloğlu
SÖSeda Öztürkmen
Seda Öztürkmen
SKSuar Çakı Kılıç
Suar Çakı Kılıç
AYAkif Yeşilipek
Akif Yeşilipek

24 February 2022 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
MYM. Akif Yesilipek
M. Akif Yesilipek
VUVedat Uygun
Vedat Uygun
AKAlphan Kupesiz
Alphan Kupesiz
GKGulsun Karasu
Gulsun Karasu
GOGulyuz Ozturk
Gulyuz Ozturk
AAAli Bülent Antmen
Ali Bülent Antmen

21 June 2020 in TURKISH JOURNAL OF BIOLOGY
Verified
Journal Article
Open access
CIHAN TASTANCIHAN TASTAN
CIHAN TASTAN
BYBulut Yurtsever
Bulut Yurtsever
GKGözde Sir Karakuş
Gözde Sir Karakuş
DKDerya Di̇lEk Kançaği
Derya Di̇lEk Kançaği
SDSevda Demir
Sevda Demir
EOErcüment Ovali
Ercüment Ovali
The novel coronavirus pneumonia, which was named later as coronavirus disease 2019 (COVID-19), is caused by the severe acute respiratory syndrome coronavirus 2, namely SARS-CoV-2. It is a positive-strand RNA virus that is the seventh coronavirus known to infect humans. The COVID-19 outbreak presents enormous challenges for global health behind the pandemic outbreak. The first diagnosed patient in Turkey has been reported by the Republic of Turkey Ministry of Health on March 11, 2020. In May, over 150,000 cases in Turkey, and 5.5 million cases around the world have been declared. Due to the urgent need for a vaccine and antiviral drug, isolation of the virus is crucial. Here, we report 1 of the first isolation and characterization studies of SARS-CoV-2 from nasopharyngeal and oropharyngeal specimens of diagnosed patients in Turkey. This study provides an isolation and replication methodology,and cell culture tropism of the virus that will be available to the research communities.

16 November 2022 in Pediatric Transplantation
Verified
Journal Article
Closed access
VUVedat Uygun
Vedat Uygun
SKSevgi Keleş
Sevgi Keleş
HDHayriye Daloğlu
Hayriye Daloğlu
SÖSeda Öztürkmen
Seda Öztürkmen
KYKoray Yalcin
Koray Yalcin
AYAkif Yeşilipek
Akif Yeşilipek

1 June 2019 in Gene
Verified
Journal Article
Closed access
GKGamze Koçak
Gamze Koçak
BGBanu Nur Güzel
Banu Nur Güzel
EMErcan Mıhçı
Ercan Mıhçı
OKOsman Alphan Kupesiz
Osman Alphan Kupesiz
KYKoray Yalcin
Koray Yalcin
AMAyşe Esra Manguoğlu
Ayşe Esra Manguoğlu

22 February 2021 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
KYKoray Yalcin
Koray Yalcin
BPBerrin Pehlivan
Berrin Pehlivan
SCSuna Celen
Suna Celen
EBElif Gulsah Bas
Elif Gulsah Bas
CKCanan Kabakci
Canan Kabakci
AYAkif Yesilipek
Akif Yesilipek
Background: Total body irradiation (TBI) is the cornerstone of conditioning regimens in pediatric hematopoietic stem cell transplantation for acute lymphoblastic leukemia. As the late effects and survival comparison between TBI and chemotherapy were well analyzed before, in this study, we aim to focus on the first 100 days and early complications of transplantation. Methods: This retrospective study involves 72 pediatric patients (0 to 18 y) underwent first hematopoietic stem cell transplantation for acute lymphoblastic leukemia between October 2015 and May 2019. Patients are divided into 2 groups regarding conditioning regimens. Conditionings includes either TBI 1200 cGy/6 fractions/3 days and etoposide phosphate or busulfan, fludarabine, and thiotepa. Busulfan was administered IV and according to body weight. Results: The incidences of acute graft versus host disease grade 2 to 4, veno-occlusive disease, capillary leakage syndrome, thrombotic microangiopathy, blood stream infection, hemorrhagic cystitis and posterior reversible encephalopathy syndrome before day 100 were similar for both conditioning regimens; however, patients received TBI-based conditioning had significantly longer neutrophil engraftment time (17.5 vs. 13 d, P=0.001) and tended to have more engraftment syndrome (ES) (45.5% for TBI vs. 24.0% for chemotherapy, P=0.069). Multivariate analysis showed that TBI-based conditioning was associated with a longer neutrophil engraftment time (hazard ratio [HR]=1.20, P=0.006), more cytomegalovirus (CMV) reactivation (HR=3.65, P=0.038) and more ES (HR=3.18, P=0.078). Conclusions: Our findings support chemotherapy-based regimens with early neutrophil engraftment, less ES and CMV reactivation compared with TBI. Although there is no impact on survival rates, increased incidence of ES and CMV reactivation should be considered in TBI-based regimens.